Novo Nordisk announced today that the FDA has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes.
